Table 2 FLT3 inhibitors in clinical trials
From: Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights
Study Agents | Other agents | Disease | Dosage | Clinical trails | No Pts | Response | Reference |
|---|---|---|---|---|---|---|---|
Sorafenib | Â | Flt3-ITD+ Relapsed and refractory AML | 200 mg-800 mg qd | retrospective | 26 | CHR: 88% | [25] |
Sorafenib | as part of induction therapy and salvage | FLT3+AML, untreated Relapsed | Â | retrospective | 128 | CR/CRp: 7% | [26] |
Sorafenib | Â | FLT3+AML Relapsed and refractory | 800 mg q.d | retrospective | 8 | CR: 25% | [27] |
Sorafenib | Idarubicin, cytarabine | FLT3+AML untreated | 400 mg po bid ×7 d | Phase II | 18 | CR/CRp: 94% | [28] |